- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05414734
Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Characteristics of HHT120 in Healthy Subjects (HHT120)
June 10, 2022 updated by: Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
A Single and Multiple Assending Doses Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic Characteristics and Food Effect After Administration of HHT120 Capsule in Healthy Subjects
This is a first in human clinical trial with HHT120.
The purpose of this study is to characterize the safety, pharmacokinetic (PK) and Pharmacodynamic (PD) profile of single and multiple twice-daily doses of HHT120 in healthy Subjects and to assess the effects of food on the PK profile of single-dose of HHT120 in healthy Subjects.
Study Overview
Detailed Description
There are 3 parts of the study:
Part 1: Single asending dose trial; Part 2: Multiple asending dose trial; Part 3: Food effect trial ( 2-Period Crossover)
Study Type
Interventional
Enrollment (Anticipated)
92
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Binglin Cui
- Phone Number: 021-61106060
- Email: cuibinglin@huahaipharm.com
Study Locations
-
-
Jiangsu
-
Wuxi, Jiangsu, China
- Affiliated Hospital of Jiangnan University
-
Contact:
- Yiqing Zhao
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 43 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects who understand and are willing to follow the clinical trial protocol to complete the study and sign the informed consent voluntarily
- ≥50 kg, BMI 19.0-26.0 kg/m2 (including the critical value);
- Those who have been proved healthy by medical history inquiry, physical examination and laboratory examination.
Exclusion Criteria:
- Have a blood coagulation dysfunction or bleeding tendency, such as repeated bleeding gums, or nearly six months increased risk of bleeding events, or platelet count < 100 x 109 / L, or always have intracranial hemorrhage (after the accident, for example), gastrointestinal bleeding, purpura, or with active pathological bleeding, bleeding or have any family history, etc.
- History of motor system, nervous/psychiatric system, endocrine system, blood circulation system, respiratory system, digestive system, urinary system, reproductive system abnormalities or existing diseases mentioned above, which the researcher judged to be clinically significant;
- History of drug or food allergy, or are allergic to the active ingredients of the test drug and any excipient ingredients;
- History of postural hypotension, fainting or coma;
- High risk factors of TdP (hypokalemia, hypomagniemia, bradycardia, heart failure, hereditary long QT syndrome, etc.);
- QTc interval greater than 450ms during screening;
- Undergone surgery within 3 months prior to or during screening, or have undergone surgery that affects drug absorption, distribution, metabolism or excretion, or plan to undergo surgery during the study period;
- Blood donation or massive blood loss (≥400 mL) within 3 months before screening or during screening (except female menstrual period);
- History of drug abuse or positive urine drug screening (morphine, THC, methylamphetamine, dimethylene dioxy-amphetamine, ketamine) within 5 years before screening;
- Excessive consumption of tea, coffee or caffeinated beverages (more than 8 cups per day, 1 cup =250 mL) within 3 months prior to screening or during screening;
- Drank regularly within 3 months prior to screening or during screening, i.e. drinking more than 14 units of alcohol per week (1 unit =360 mL beer or 45mL 40% alcohol spirits or 150mL wine), who could not abstain from drinking during the test, or whose alcohol breath test results were > 0 mg/100mL;
- Smoking ≥5 cigarettes per day in the previous 3 months in the screening period; Or unable to stop using any tobacco products in the treatment period;
- Consumed a large amount of drinks or food (such as grapefruit, grapefruit juice, grapefruit jam, etc.) rich in grapefruit, pomelo, star fruit, mango and dragon fruit within the previous 14 days prior to screening; Or any beverage or food containing grapefruit (i.e. grapefruit), pomelo, star fruit, mango, dragon fruit within 48 hours before the first dose;
- Special dietary requirements, unable to follow the uniform diet or dysphagia;
- Lactose intolerant (who had diarrhea after drinking milk);
- Have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health care products within 14 days prior to screening;
- Received vaccination within 28 days prior to or during screening;
- Have participated in other clinical trials within 3 months prior to or during screening or who are not themselves participating in clinical trials;
- Pregnant or lactating women, or abnormal pregnancy tests that are clinically significant as determined by the investigator; Male subjects (or their partners) or female subjects who have planned to have children during the entire study period and within 6 months after the study end and are unwilling to use one or more non-drug contraceptive methods (e.g., complete abstinence, condoms, vasectomy, etc.) during the study period;
- Female subjects with irregular menstruation or menstrual disorder (including menstrual cycle disorder, menstrual disorder and menorrhagia);
- Those who cannot tolerate venipuncture or have difficulty in collecting blood;
- Abnormal physical examination, blood routine examination, blood biochemistry, coagulation function, urine routine examination, 12-lead electrocardiogram examination, chest X-ray examination and clinical significance determined by the investigator;
- Abnormal vital signs and abnormal retest;
- Hepatitis B surface antigen, treponema pallidum antibody, human immunodeficiency virus antibody and hepatitis C antibody are abnormal and clinically significant as determined by researchers;
- The investigator considers that the subjects are not suitable to participate in the study for other reasons or the subjects withdraw from the study for their own reasons.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SAD HHT120
Subjects will receive a single dose of HHT120 from 7 doses.
|
Capsule, oral administration
Other Names:
|
Placebo Comparator: SAD Placebo
Subjects will receive a single dose of matched Placebo.
|
Capsule, oral administration
|
Experimental: MAD HHT120
Subjects will receive a mutiple-dose of HHT120 twice daily for 7 days from 3 doses.
|
Capsule, oral administration
Other Names:
|
Placebo Comparator: MAD Placebo
Subjects will receive a mutiple-dose of matched placebo twice daily for 7 days.
|
Capsule, oral administration
|
Experimental: FE K-C
Subjects will receive a single dose of HHT120 in the morning in fasted condition in Period 1; followed by a single dose of HHT120 administered in the morning in fed condition in Period 2. A washout period of 7 days will be maintained between 2 periods.
|
Capsule, oral administration
Other Names:
|
Experimental: FE C-K
Subjects will receive a single dose of HHT120 in the morning in fed condition in Period 1; followed by a single dose of HHT120 administered in the morning in fasted condition in Period 2. A washout period of 7 days will be maintained between 2 periods.
|
Capsule, oral administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vital signs
Time Frame: Up to Day 14
|
Abnormal changes in vital signs from baseline
|
Up to Day 14
|
Physical examination
Time Frame: Up to Day 14
|
Abnormal changes in physical examination from baseline
|
Up to Day 14
|
Laboratory examination
Time Frame: Up to Day 14
|
Abnormal changes in laboratory examination from baseline
|
Up to Day 14
|
Electrocardiogram
Time Frame: Up to Day 14
|
Abnormal changes in electrocardiogram from baseline
|
Up to Day 14
|
Chest radiography
Time Frame: Up to Day 14
|
Abnormal changes in chest radiography from baseline
|
Up to Day 14
|
Adverse events
Time Frame: Up to Day 14
|
Incidence of adverse events, serious adverse events, adverse events of special interest
|
Up to Day 14
|
Maximum tolerable dose (MTD)
Time Frame: Up to Day 14
|
Maximum tolerable dose (MTD)
|
Up to Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Cmax
Time Frame: Up to Day 4
|
Cmax of single dose administration
|
Up to Day 4
|
Part 1: Tmax
Time Frame: Up to Day 4
|
Tmax of single dose administration
|
Up to Day 4
|
Part 1: t1/2
Time Frame: Up to Day 4
|
t1/2 of single dose administration
|
Up to Day 4
|
Part 1: Vz/F
Time Frame: Up to Day 4
|
Vz/F of single dose administration
|
Up to Day 4
|
Part 1: CLz/F
Time Frame: Up to Day 4
|
CLz/F of single dose administration
|
Up to Day 4
|
Part 1: AUC
Time Frame: Up to Day 4
|
AUC of single dose administration
|
Up to Day 4
|
Part 2: Cmax,ss
Time Frame: Up to Day 10
|
Cmax,ss of multiple dose administration
|
Up to Day 10
|
Part 2: AUC,ss
Time Frame: Up to Day 10
|
AUC,ss of multiple dose administration
|
Up to Day 10
|
Part 2: Tmax,ss
Time Frame: Up to Day 10
|
tmax,ss of multiple dose administration
|
Up to Day 10
|
Part 2: Cmin,ss
Time Frame: Up to Day 10
|
Cmin,ss of multiple dose administration
|
Up to Day 10
|
Part 2: Cav,ss
Time Frame: Up to Day 10
|
Cav,ss of multiple dose administration
|
Up to Day 10
|
Part 2: t1/2
Time Frame: Up to Day 10
|
t1/2 of multiple dose administration
|
Up to Day 10
|
Part 2: MRTss
Time Frame: Up to Day 10
|
MRTss of multiple dose administration
|
Up to Day 10
|
Part 2: Accumulation index
Time Frame: Up to Day 10
|
accumulation index of multiple dose administration
|
Up to Day 10
|
Part 1 & Part 2: aPTT, INR and TT
Time Frame: Up to Day 10
|
Maximum percentage of aPTT, INR and TT to baseline (Emax)
|
Up to Day 10
|
Part 3: Cmax in fasted or fed condition
Time Frame: Up to Day 4
|
Geometric mean ratios of Cmax (fed/fasted) and their 90% confidence intervals
|
Up to Day 4
|
Part 3: AUC in fasted or fed condition
Time Frame: Up to Day 4
|
Geometric mean ratios of AUC (fed/fasted) and their 90% confidence intervals
|
Up to Day 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yiqing Zhao, Affiliated Hospital of Jiangnan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
July 1, 2022
Primary Completion (Anticipated)
February 15, 2023
Study Completion (Anticipated)
March 1, 2023
Study Registration Dates
First Submitted
May 27, 2022
First Submitted That Met QC Criteria
June 7, 2022
First Posted (Actual)
June 10, 2022
Study Record Updates
Last Update Posted (Actual)
June 15, 2022
Last Update Submitted That Met QC Criteria
June 10, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- DTYX21037PⅠ
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet